HOME >> BIOLOGY >> NEWS
May: Multiple Sclerosis Awareness Month -- latest research is good news

Montreal, QC -- May is Multiple Sclerosis Month and there is no better way of raising awareness for this unpredictable and often debilitating disease then by highlighting the latest research that might offer hope for the 55 to 75, 000 sufferers across Canada. A new drug under investigation for Multiple Sclerosis (MS) appears to be safe and effective according to studies involving researchers at the Montreal Neurological Institute. The studies, presented this week at the American Academy of Neurologys (AAN) 59th Annual Meeting in Boston, also provide deeper insight into the biology of this complex disease. Canadians have one of the highest rates of Multiple Sclerosis (MS) in the world with approximately 1,000 new cases of MS diagnosed each year. MS is the most common neurological disease affecting young adults in Canada and affects 18% of all Quebecers.

The Phase I and Phase II studies involved people in Canada and the USA with relapsing-remitting MS, in which symptoms flare up and then subside. Treatment with the drug rituximab significantly reduced the number of new brain lesions and the frequency of relapses, times when symptoms of MS flare up.

Rituximab is a therapeutic antibody that selectively targets and depletes a set of immune cells called B-cells by binding to a specific protein on their surface.

"This is the first drug to selectively target B-cells in MS and the significance of its effectiveness is two-fold," says Dr. Amit Bar-Or, neurologist at the Montreal Neurological Institute (MNI) at McGill University, Montreal, Canada and lead investigator in the Phase I study. "Not only might it present a significantly improved therapy for patients with relapsing-remitting MS, but it provides a clearer picture of the role that B-cells play in the disease. Its a particularly exciting time and we think meaningful to advancing treatment options for patients."

The Phase I trial was primarily designed to assess the safety
'"/>

Contact: Anita Kar
anita.kar@mcgill.ca
514-398-3376
Montreal Neurological Institute and Hospital
2-May-2007


Page: 1 2

Related biology news :

1. Alleviating the burden of Multiple Sclerosis
2. Multiple sclerosis progression linked to immune-cell substance
3. Multiple genes permit closely related fish species to mix and match their color vision
4. Multiple genetic flavors may explain autism
5. Multiple sightings of long-lost woodpecker reported
6. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
7. Brain Awareness Week teaches kids how their brains work
8. Breast Cancer Month story tips from Georgetown University Medical Center
9. National Academies advisory: Feb. 15 program for African-American History Month
10. AAAS decries latest stem cell veto
11. Brain, size and gender surprises in latest fossil tying humans, apes and monkeys

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, LLC, a ... GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This novel ... and provide visual documentation of monoclonality for use in cell line development. ...
(Date:9/18/2017)... 2017   Montrium , a growing leader in Electronic ... with a groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic ... MAPS ... PTSD ... Therapy Designation to MDMA for the treatment of Posttraumatic Stress Disorder ...
(Date:9/14/2017)... PA and London UK (PRWEB) , ... September ... ... will gather the most innovative minds in pharma and biotech at the third ... a two-day collaborative conference that brings together the world’s most progressive clinical research ...
(Date:9/14/2017)... ... 14, 2017 , ... AIM Global, the worldwide standards agency for AIDC and ... 2017 Case Study Competition for AIDC. The award is given to those in ... push the adoption of automated data collection systems further. The TRACTUS platform, by ...
Breaking Biology Technology:
Cached News: